KR100530843B1 - Anti-inflammatory composition containing paecilomyces extract and cordyceps extracts as effective composition - Google Patents

Abstract

The present invention relates to an anti-inflammatory composition comprising Cordyceps sinensis extract as an active ingredient. The present invention provides an anti-inflammatory composition comprising Cordyceps sinensis extract, which is excellent in inhibiting skin inflammation by inhibiting the production of interleukin-1, and safe for the human body.

Description

Anti-inflammatory composition comprising Cordyceps sinensis extract as an active ingredient {ANTI-INFLAMMATORY COMPOSITION CONTAINING PAECILOMYCES EXTRACT AND CORDYCEPS EXTRACTS AS EFFECTIVE COMPOSITION}

[TECHNICAL FIELD OF THE INVENTION]

The present invention relates to an anti-inflammatory composition comprising Cordyceps sinensis extract as an active ingredient, and more particularly, to an anti-inflammatory composition comprising Cordyceps sinensis extract which inhibits the production of skin erythema by inhibiting the production of proinflammatory cytokines such as interleukin-1. It is about.

[Private Technology]

Inflammation is a series of defensive reactions in which cells or tissues are damaged by any cause to minimize the response and restore the damaged area. Inflammation causes physical factors such as trauma, burns, frostbite, radiation, chemical factors such as acids, and immunological factors due to antibody reactions. The mechanism of inflammation is very complex but is regulated through cytokine networks, and there are many types of cytokines that make up these networks.

IL-1 (interleukin-1) is a cytokine that plays an important role in inducing infections and diseases of the immune and nervous systems (Dinarello, CA, Blood 87 (6): 2095-147, 1996), fever, loss of appetite, It is involved in increased lymphocyte response, activity of the hypothalamic-pituitary-adrenal axis. Interleukin-1 is also produced when skin or epidermal cells are exposed to the external environment. Interleukin-1 is thought to play an important role in the inflammatory response and is predominantly in the early stages of the bioreaction, because it is a pro-inflammatory cytokine ( Respir Med 2002 96: 553-8, Serum pro-inflammatory cytokines and its relationship to clinical parameters in lung cancer patients with reactive thrombocytosis). Interleukin-1 is known to play a particularly important role in the skin's inflammatory response, and its production is increased by keratinocytes in inflammatory diseases of the skin, including irritant dermatitis or allergic dermatitis.

  In order to control the inflammation of the skin, efforts have been made to remove the inflammatory source to eliminate inflammation, to develop a medicament to reduce the bioreaction and symptoms, but no attempt has been made to control the inflammatory response by directly inhibiting interleukin-1. .

The substances used for anti-inflammatory purposes so far include flufenamic acid, ibuprofen, benzydamine and indometacine, and hydrocortisone and prednisolone as steroid systems. prednisolone) and dexamethasone (Kim Chang-jong, Pathophysiology, Hallym Co., p61-69, 1988) and also allantoin, azulene, ε-aminokiproic acid, licoriceic acid and its derivatives (β-glycilechinic acid, glychile) Hydrophilic acid derivatives) and the like are known to have an anti-inflammatory effect (Ministry of Gwangjeongjeong, New Cosmetics, Namsan Sugar, p162, 1993). However, indomethacin and hydrocortisone may cause side effects when used as a drug for a long time, and licorice acid and its derivatives are difficult to stabilize or have poor solubility, which makes it difficult to achieve practical effects due to the concentration limitation. have. In addition, the anti-inflammatory agents known to date are problematic in terms of safety and stability in cosmetic formulations and their use is limited. Therefore, effective management of inflammation requires the development of a cosmetic or pharmaceutical composition that inhibits the production of early inflammatory cytokines such as interleukin-1 while being safe for prolonged use.

Accordingly, an object of the present invention is to provide a Cordyceps sinensis extract that inhibits the production of interleukin-1 to control skin inflammation.

It is an object of the present invention to provide a Cordyceps sinensis extract that reduces skin erythema.

It is an object of the present invention to provide an anti-inflammatory composition comprising as an active ingredient Cordyceps sinensis extract that is harmless to the human body.

In order to achieve the above object, the present invention provides an anti-inflammatory composition comprising Cordyceps sinensis extract as an active ingredient.

In another aspect, the present invention provides an interleukin-1 production inhibitory composition comprising Cordyceps sinensis extract as an active ingredient.

  Hereinafter, the present invention will be described in detail.

In order to search for substances capable of anti-inflammatory action, the present inventors studied various plant extracts and found that Cordyceps sinensis extract has an excellent effect on inhibiting skin inflammation by inhibiting the production of interleukin-1. On the basis of this, the present invention has been completed.

Cordyceps sinensis of the present invention is a common cordyceps, preferably Paecilomyces japonica and Cordyceps sp. Cordyceps.

Cordyceps sinensis extract of the present invention is from the group consisting of water, methanol, ethanol, petroleum ether, chloroform, ethyl acetate, normal butanol, acetone, 1,3-butylene glycol, hexane, diethyl ether, normal propanol and iso-propanol It is extracted with one or more selected solvents. The extraction method is preferably dissolved in a mixture containing purified water: solvent 1: 1 to 0.5 to 1 to 50 to 200 parts by weight based on 100 weight of Cordyceps sinensis powder, and then fractionated or extracted, filtered and concentrated under reduced pressure. .

Cordyceps sinensis extract has an anti-inflammatory effect by inhibiting the production of interleukin-1 as well as inhibiting erythema formation of the skin. In addition, Cordyceps sinensis extract is harmless to the human body, and does not cause side effects from long-term use.

Accordingly, the present invention provides an anti-inflammatory composition or interleukin-1 production inhibitory composition comprising Cordyceps sinensis extract as an active ingredient.

The anti-inflammatory composition or interleukin-1 production inhibitory composition may include the Cordyceps sinensis extract by adjusting the content according to the purpose and method of use, preferably 0.00001 to 10% by weight.

The anti-inflammatory composition or interleukin-1 production inhibitory composition of the present invention may further comprise a pharmaceutically acceptable carrier or excipient. Representative carriers or excipients include water, dextrins, and saline. Anti-inflammatory compositions or interleukin-1 production inhibitory compositions can be used as cosmetic compositions, detergent compositions and medicaments. When used as a cosmetic composition, the formulation may be a softening lotion, a skin, a nourishing cream, a massage cream, an essence, a pack, a soap, a shampoo, a skin patch and a skin adhesive gel, and when used as a cleaning composition, it may be a face wash and a bath. have. When used as a medicament, the anti-inflammatory composition or interleukin-1 production inhibitory composition can be prepared in the form of a warning agent, granules, lotions, powders, syrups, ointments, emulsions, suspensions, tablets and injections.

The anti-inflammatory composition or interleukin-1 production inhibitory composition of the present invention is used by adjusting the amount of use according to the use purpose and the state of the application site, for example, to apply once to three times a day at a concentration of 0.001 to 100 mg / ㎖ per day Use it as a way.

Hereinafter, examples of the present invention will be described. The following examples are only for illustrating the present invention, but the protection scope of the present invention is not limited to the following examples.

Example 1: Cordyceps Sinensis Water Extract Preparation

After purchasing Paecilomyces japonica and Cordyceps sp. Cordyceps, they were washed with purified water, dried and powdered. 100 g of Cordyceps sinensis powder was dissolved in 500 ml of water, extracted at 20 ° C. for 5 days, and 300 mesh After filtration through a filter cloth, the mixture was left for 10 days at 10 ° C. for low temperature aging, and filtered through Whatman No. 2 filter paper. The filtrate was concentrated under reduced pressure at 60 ° C. in a distillation apparatus equipped with a cooling condenser, and dried to prepare Cordyceps sinensis water extract.

Example 2: Cordyceps Sinensis Ethanol Extract Preparation

Cordyceps ethanol extract was prepared in the same manner as in Example 1, using 50% ethanol instead of water as an extraction solvent.

Example 3: Cordyceps Sinensis Extract

The same procedure as in Example 1 was carried out, except that Cordyceps sinensis extract was prepared using 50% methanol instead of water as an extraction solvent.

Examples 4 to 9: Cordyceps sinensis extract preparation

100 g of Cordyceps sinensis powder was first extracted with 70% ethyl alcohol, concentrated under reduced pressure, and purified water was added to separate the non-aqueous extract and the primary water-soluble fraction. Extraction solvents of petroleum ether, chloroform, ethyl acetate and butanol were sequentially added to the aqueous fraction, and the fractions of the respective extraction solvents were separated at room temperature. In addition, the fraction remaining after the butanol fraction as a secondary water-soluble fraction.

The water-insoluble fraction, the petroleum ether fraction, the chloroform fraction, the ethyl acetate fraction, the butanol fraction and the secondary water-soluble fraction separated by the above method were concentrated under reduced pressure and dried, respectively, to extract Cordyceps sinensis non-aqueous extract (Example 4) and Cordyceps petroleum ether. An extract (Example 5), Cordyceps sinensis chloroform extract (Example 6), Cordyceps sinensis ethyl acetate extract (Example 7), Cordyceps sinensis butanol extract (Example 8) and Cordyceps sinensis water-soluble extract (Example 9) were obtained.

The dry weight of Cordyceps sinensis extract obtained by the method of Examples 1 to 9 is shown in Table 1 below.

sample Extraction solvent Dry weight (g) Example 1 Water extract Cordyceps cordyceps Purified water 11.2 Snowflake Cordyceps 10.4 Example 2 Ethanol extract Cordyceps cordyceps 50% ethanol 12.5 Snowflake Cordyceps 11.2 Example 3 Methanol extract Cordyceps cordyceps 50% methanol 13.2 Snowflake Cordyceps 12.2 Example 4 Water-insoluble extract Cordyceps cordyceps Water-insoluble fraction 0.4 Example 5 Petroleum Ether Extract Snowflake Cordyceps Petroleum ether 0.2 Example 6 Chloroform extract Cordyceps cordyceps chloroform 0.6 Example 7 Ethyl acetate extract Snowflake Cordyceps Ethyl acetate 0.3 Example 8 Butanol extract Cordyceps cordyceps Butanol 2.7 Example 9 Second Water Soluble Extract Snowflake Cordyceps Secondary water-soluble fraction 1.5

 Experimental Example 1 Inhibitory Effect of Cordyceps Sinensis Extract on Interleukin-1 Production

The keratinocytes obtained from the epidermis were cultured, treated with 1% SDS to 0.1% in the culture medium, and then waited 24 hours to measure the concentration of interleukin-1 in the cells. The concentration of interleukin-1 in cells not treated with SDS was about 200 pg / ml, whereas the concentration of intraleukin-1 in cells treated with SDS increased to 400 pg / ml. In addition, dexamethasone, a steroid, was used as a positive control. The concentration of interleukin-1 in the cells treated with dexamethasone was 220 pg / ml, which showed an inhibitory effect of about 90% of interleukin-1 production.

Cordyceps sinensis extracts of Examples 1 to 3 were treated to keratinocytes in the same manner as SDS, and then the inhibitory effect of interleukin-1 production was measured and shown in Table 2.

sample  Interleukin-1 Production Inhibition Rate Example 1 Water extract Cordyceps cordyceps 45% Snowflake Cordyceps 47% Example 2 Ethanol extract Cordyceps cordyceps 75% Snowflake Cordyceps 94% Example 3 Methanol extract Cordyceps cordyceps 58% Snowflake Cordyceps 68% SDS treatment group 0 % Dexamethasone treatment group 90%

In Table 2, Cordyceps sinensis extracts of Examples 1 to 3 exhibited excellent interleukin-1 production inhibition rate, and particularly, the inhibition rate of Snow Cordyceps sinus ethanol extract of Example 2 was very high.

Experimental Example 2: Effect of erythema

A site where no treatment was applied to the volunteer's skin, a site where dexamethasone ointment was applied, and a site where Example 3 (1%) of Cordyceps sinensis was applied were prepared and irradiated with ultraviolet (100 mJ / cm ² ). Even after irradiation, dexamethasone and Cordyceps sinensis extract were applied once a day. The erythema index was measured before and after 2, 5, and 6 days with mexameter to prevent and reduce erythema outbreak. The results are shown in Table 3 below.

Control Dexamethasone Example 3 Just before the investigation 571.33 557.33 569.67 2 days after investigation 657.33 642.00 621.67 5 days after investigation 614.67 578.67 599.00 6 days after investigation 619.00 588.33 586.67

In Table 3, Cordyceps sinensis extract showed a superior skin protection effect compared to the control, and showed an almost equivalent effect to the strong steroid, dexamethasone, it was confirmed that the erythema development inhibitory effect is excellent.

Example 10 Preparation of Softened Longevity Containing Cordyceps Sinensis Extract

Cordyceps sinensis extract 0.1 wt%, glycerin 5.0 wt%, 1,3-butylene glycol 3.0 wt%, Fiji 1500 1.0 wt%, allantoin 0.1 wt%, DL-panthenol 0.3 wt%, EDTA-2NA 0.02 wt%, benzophenone -9 0.04% by weight, sodium hyaluronate 5.0% by weight, ethanol 10.0% by weight, octyldodeces-16% by weight, polysorbate 20% by weight, and a small amount of preservatives, flavors, pigments and residual purified water Longevity was prepared.

Example 11: Preparation of Converging Cosmetic Water Containing Cordyceps Sinensis Extract

Cordyceps sinensis extract 0.1 wt%, glycerin 2.0 wt%, 1,3-butylene glycol 2.0 wt%, Fiji 1500 1.0 wt%, allantoin 0.2 wt%, DL-panthenol 0.2 wt%, sodium hyaluronate 3.0 wt%, ethanol 15.0% by weight, octyldodeces-16 0.2% by weight, polysorbate 20 0.3% by weight, witch hazel extract 2.0% by weight, and a small amount of citric acid, preservatives, fragrances, pigments and the residual amount of purified water were mixed. .

Example 12 Preparation of Nutritional Cream Containing Cordyceps Sinensis Extract

Cordyceps sinensis extract 0.1 wt%, stearyl alcohol 6.0 wt%, stearic acid 2.0 wt%, concentrated glycerin 1.0 wt%, squalane 9.0 wt%, 1,3-butylene glycol 6.0 wt%, polysorbate 60 1.5 wt%, polyethylene glycol 1000 4.0% by weight, cured lanolin 4.0% by weight, octyl dodecanol 10.0% by weight, sorbitan stearate 0.8% by weight, triethanolamine 0.5% by weight, and an appropriate amount of paraoxyansi-acid ester, a fragrance, a pigment and the remaining purified water To prepare a nourishing cream containing lucha extract.

Example 13: Preparation of Massage Cream Containing Cordyceps Sinensis Extract

Cordyceps sinensis extract, 0.1 wt%, petrolatum 7 wt%, liquid paraffin 10 wt%, beeswax 2 wt%, polysorbate 2.5 wt%, squalene 3 wt%, glycerin 4 wt%, propylene glycol 6 wt%, and a suitable amount of preservative The remaining amount of purified water was mixed to prepare a massage cream.

Example 14 Preparation of Essence Containing Cordyceps Sinensis Extract

Cordyceps sinensis extract 0.1 wt%, cyclomethicone 15.0 wt%, caprylic capric triglyceride 3.0 wt%, mineral oil 3.0 wt%, beeswax 1.0 wt%, tocopherol 1.0 wt%, cetyldimethicone copolyol 3.0 wt%, glycerin 5.0 An essence was prepared by mixing a weight percent, 3.0 weight percent magnesium sulfate, and an appropriate amount of paraoxybenzoic acid ester with a residual amount of purified water.

Example 15 Preparation of a Pack Containing Cordyceps Sinensis Extract

Cordyceps sinensis extract 0.1 wt%, glycerin 5.0 wt%, propylene glycol 4.0 wt%, polyvinyl alcohol 15.0 wt%, ethanol 8.0 wt%, polyoxyethylene oleyl ethyl 1.0 wt%, paraoxybenzoic acid methyl 0.2 wt%, and proper amount The pack was prepared by mixing the aroma and the remaining amount of purified water.

Example 16: Preparation of Soap Containing Cordyceps Sinensis Extract

Cordyceps sinensis extract 0.1% by weight, palm oil 66% by weight, palm kernel oil 32% by weight, and other flavors were mixed to prepare a soap containing a green tea extract.

Example 17 Preparation of an external preparation for skin containing Cordyceps sinensis extract

Cordyceps sinensis extract 0.1% by weight, diethyl sebacate 8.0% by weight, lead content 5.0% by weight, polyoxyethylene oleyl-ether phosphate (EO4) 6.0% by weight, and a suitable amount of paraoxybenzoic acid ester and the remaining amount of petrolatum cordyceps extract A skin external ointment was prepared.

Anti-inflammatory composition comprising Cordyceps sinensis extract of the present invention has an excellent anti-inflammatory effect by inhibiting the production of interleukin-1 and inhibiting erythema in humans, it can be used safely in the human body.

Claims (6)

Paecilomyces japonica or Cordyceps sp. Cordyceps sinensis extract as an active ingredient, the extract is an aqueous ethanol solution containing water, water and ethanol in a volume ratio of 1: 0.5 to 1, and water and methanol 1: 1: an anti-salt composition, which is extracted with one solvent selected from the group consisting of an aqueous methanol solution containing a volume ratio of 0.5 to 1. The anti-inflammatory composition according to claim 1, wherein the extract of Snow Cordyceps sinensis or Cordyceps genus Cordyceps sinensis inhibits the production of interleukin-1. delete delete The composition of claim 1, wherein the composition comprises Cordyceps sinensis extract in an amount of 0.00001 to 10% by weight. The composition of claim 1, wherein the composition is a cosmetic composition.